Zentalis Pharmaceuticals (ZNTL)

• Market cap: $314M
• 1 day: 4.26%
• 5 days: 7.3%
• 1 month: 59.78%
• 3 months: 83.75%
• 6 months: 234.09%
• Year to date: 221.9%
• 1 year: 250%
• 5 years: -92.48%
• 10 years: -80.99%
• Sector: Healthcare
• Industry: Biotechnology

About: Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Employees: 106